Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary car...
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center
About this item
Full title
Author / Creator
Publisher
Boston: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Springer US
Subjects
More information
Scope and Contents
Contents
Aggressive pituitary adenomas (PAs) are clinically challenging for endocrinologists and neurosurgeons due to their locally invasive nature and resistance to standard treatment (surgery, medical or radiotherapy). Two pituitary-directed drugs have recently been proposed: temozolomide (TMZ) for aggressive PA, and pasireotide for ACTH-secreting PA. We...
Alternative Titles
Full title
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1668247360
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1668247360
Other Identifiers
ISSN
0167-594X
E-ISSN
1573-7373
DOI
10.1007/s11060-014-1702-0
